Glancy Prongay & Murray LLP Announces Investigation of G1 Therapeutics, Inc.

Glancy Prongay & Murray LLP (GPM) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors and officers possible violations of state laws.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 26, 2021
Information
Tags: 
Legal, Professional services
Geotags: 
United States, NEW YORK
⚠generated by AI ↴
Summary
Key Points: 
  • Glancy Prongay & Murray LLP (GPM) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors and officers possible violations of state laws.
  • If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210126006040/en/


Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors’ and officers’ possible violations of state laws.

If you purchased G1 Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at [email protected], or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Copyright: 
Copyright Business Wire 2021